Literature DB >> 20056347

Parotid gland function after radiotherapy: the combined michigan and utrecht experience.

Tim Dijkema1, Cornelis P J Raaijmakers, Randall K Ten Haken, Judith M Roesink, Pètra M Braam, Anette C Houweling, Marinus A Moerland, Avraham Eisbruch, Chris H J Terhaard.   

Abstract

PURPOSE: To analyze the combined and updated results from the University of Michigan and University Medical Center Utrecht on normal tissue complication probability (NTCP) of the parotid gland 1 year after radiotherapy (RT) for head-and-neck (HN) cancer. PATIENTS AND METHODS: A total of 222 prospectively analyzed patients with various HN malignancies were treated with conventional and intensity-modulated RT. Stimulated individual parotid gland flow rates were measured before RT and 1 year after RT using Lashley cups at both centers. A flow ratio <25% of pretreatment was defined as a complication. The data were fitted to the Lyman-Kutcher-Burman model.
RESULTS: A total of 384 parotid glands (Michigan: 157; Utrecht: 227 glands) was available for analysis 1 year after RT. Combined NTCP analysis based on mean dose resulted in a TD(50) (uniform dose leading to 50% complication probability) of 39.9 Gy and m (steepness of the curve) of 0.40. The resulting NTCP curve had good qualitative agreement with the combined clinical data. Mean doses of 25-30 Gy were associated with 17-26% NTCP.
CONCLUSIONS: A definite NTCP curve for parotid gland function 1 year after RT is presented, based on mean dose. No threshold dose was observed, and TD(50) was equal to 40 Gy. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20056347      PMCID: PMC2889151          DOI: 10.1016/j.ijrobp.2009.07.1708

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.

Authors:  A Eisbruch; R K Ten Haken; H M Kim; L H Marsh; J A Ship
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

Review 2.  The controversies and pitfalls in modeling normal tissue radiation injury/damage.

Authors:  T E Schultheiss
Journal:  Semin Radiat Oncol       Date:  2001-07       Impact factor: 5.934

Review 3.  Partial irradiation of the parotid gland.

Authors:  A Eisbruch; J A Ship; H M Kim; R K Ten Haken
Journal:  Semin Radiat Oncol       Date:  2001-07       Impact factor: 5.934

4.  Is uniform target dose possible in IMRT plans in the head and neck?

Authors:  K A Vineberg; A Eisbruch; M M Coselmon; D L McShan; M L Kessler; B A Fraass
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-04-01       Impact factor: 7.038

5.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

6.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method.

Authors:  G J Kutcher; C Burman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

7.  Complication probability as assessed from dose-volume histograms.

Authors:  J T Lyman
Journal:  Radiat Res Suppl       Date:  1985

8.  LENT SOMA tables.

Authors: 
Journal:  Radiother Oncol       Date:  1995-04       Impact factor: 6.280

9.  Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy.

Authors:  K Bjordal; S Kaasa; A Mastekaasa
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-03-01       Impact factor: 7.038

10.  Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.

Authors:  Marc W Münter; Christian P Karger; Simone G Hoffner; Holger Hof; Christoph Thilmann; Volker Rudat; Simeon Nill; Michael Wannenmacher; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

View more
  44 in total

1.  Tyrosine Kinase Inhibitors Protect the Salivary Gland from Radiation Damage by Inhibiting Activation of Protein Kinase C-δ.

Authors:  Sten M Wie; Elizabeth Wellberg; Sana D Karam; Mary E Reyland
Journal:  Mol Cancer Ther       Date:  2017-06-21       Impact factor: 6.261

Review 2.  Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.

Authors:  Arjan Vissink; James B Mitchell; Bruce J Baum; Kirsten H Limesand; Siri Beier Jensen; Philip C Fox; Linda S Elting; Johannes A Langendijk; Robert P Coppes; Mary E Reyland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-15       Impact factor: 7.038

3.  Improving IMRT-plan quality with MLC leaf position refinement post plan optimization.

Authors:  Ying Niu; Guowei Zhang; Barry L Berman; William C Parke; Byongyong Yi; Cedric X Yu
Journal:  Med Phys       Date:  2012-08       Impact factor: 4.071

4.  Predicting Patient-specific Dosimetric Benefits of Proton Therapy for Skull-base Tumors Using a Geometric Knowledge-based Method.

Authors:  David C Hall; Alexei V Trofimov; Brian A Winey; Norbert J Liebsch; Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-14       Impact factor: 7.038

5.  Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer.

Authors:  Peter van Luijk; Sarah Pringle; Joseph O Deasy; Vitali V Moiseenko; Hette Faber; Allan Hovan; Mirjam Baanstra; Hans P van der Laan; Roel G J Kierkels; Arjen van der Schaaf; Max J Witjes; Jacobus M Schippers; Sytze Brandenburg; Johannes A Langendijk; Jonn Wu; Robert P Coppes
Journal:  Sci Transl Med       Date:  2015-09-16       Impact factor: 17.956

Review 6.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

7.  Unilateral and bilateral neck SIB for head and neck cancer patients : Intensity-modulated proton therapy, tomotherapy, and RapidArc.

Authors:  Carmen Stromberger; Luca Cozzi; Volker Budach; Antonella Fogliata; Pirus Ghadjar; Waldemar Wlodarczyk; Basil Jamil; Jan D Raguse; Arne Böttcher; Simone Marnitz
Journal:  Strahlenther Onkol       Date:  2016-02-06       Impact factor: 3.621

8.  Recombinant AAV9-TLK1B administration ameliorates fractionated radiation-induced xerostomia.

Authors:  Prakash Srinivasan Timiri Shanmugam; Robert D Dayton; Senthilnathan Palaniyandi; Fleurette Abreo; Gloria Caldito; Ronald L Klein; Gulshan Sunavala-Dossabhoy
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

9.  Risk model and nomogram for dysphagia and xerostomia prediction in head and neck cancer patients treated by radiotherapy and/or chemotherapy.

Authors:  David N Teguh; Peter C Levendag; Wendimagegn Ghidey; Kees van Montfort; Stefan L S Kwa
Journal:  Dysphagia       Date:  2013-01-26       Impact factor: 3.438

10.  Xerostomia after radiotherapy. What matters--mean total dose or dose to each parotid gland?

Authors:  S Tribius; J Sommer; C Prosch; A Bajrovic; A Muenscher; M Blessmann; A Kruell; C Petersen; M Todorovic; P Tennstedt
Journal:  Strahlenther Onkol       Date:  2013-01-27       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.